These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10751080)

  • 21. [Molecular medicine and treatment of tuberculosis].
    Perel'man MI; Khomiakov IuN; Kiselev VI; Severin ES; Pal'tsev MA
    Probl Tuberk; 2001; (5):5-7. PubMed ID: 11588966
    [No Abstract]   [Full Text] [Related]  

  • 22. Drugs for tuberculosis.
    Med Lett Drugs Ther; 1993 Oct; 35(908):99-101. PubMed ID: 8412982
    [No Abstract]   [Full Text] [Related]  

  • 23. [Comparison of the proteomes of isoniazid-resistant Mycobacterium tuberculosis strains and isoniazid-susceptible strains].
    Jiang X; Gao F; Zhang WH; Hu ZY; Wang HH
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):427-31. PubMed ID: 17673015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence, not resistance, is the cause of loss of isoniazid effect.
    Wallis RS; Palaci M; Eisenach K
    J Infect Dis; 2007 Jun; 195(12):1870-1; author reply 1872-3. PubMed ID: 17492604
    [No Abstract]   [Full Text] [Related]  

  • 25. [Control of drug-sensitive and (multi-)resistant tuberculosis].
    Borgdorff MW
    Ned Tijdschr Geneeskd; 2002 Aug; 146(33):1525-7. PubMed ID: 12212497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
    Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea.
    Lee H; Cho SN; Bang HE; Lee JH; Bai GH; Kim SJ; Kim JD
    Int J Tuberc Lung Dis; 2000 May; 4(5):441-7. PubMed ID: 10815738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The characteristics of the sensitivity of Mycobacterium tuberculosis to rifampicin and isoniazid through determination of mutations in the genes rpoB, katG, inhA, oxyR, and kasA by different molecular biological assays].
    Skotnikova OI; Galkina KIu; Nosova EIu; Krasnova MA; Moroz AM
    Probl Tuberk Bolezn Legk; 2005; (8):42-5. PubMed ID: 16209020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ring-substituted quinolines as potential anti-tuberculosis agents.
    Vangapandu S; Jain M; Jain R; Kaur S; Singh PP
    Bioorg Med Chem; 2004 May; 12(10):2501-8. PubMed ID: 15110831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Changes in drug resistance of Mycobacteria in the simultaneous use of chemotherapy and intravenous infusions of dissolved ozone].
    Belianin II; Shmelev EI
    Probl Tuberk Bolezn Legk; 2004; (7):32-5. PubMed ID: 15379039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuberculosis drug resistance: summary report for 2003.
    Can Commun Dis Rep; 2004 May; 30(10):93-5. PubMed ID: 15174496
    [No Abstract]   [Full Text] [Related]  

  • 32. Evolution in the resistance of Mycobacterium tuberculosis to anti-tuberculosis drugs in Nicaragua.
    Chacón L; Lainez M; Rosales E; Mercado M; Caminero JA
    Int J Tuberc Lung Dis; 2009 Jan; 13(1):62-7. PubMed ID: 19105880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a standardised multidrug-resistant/extensively drug-resistant tuberculosis assessment and monitoring tool.
    Migliori GB; Sotgiu G; Jaramillo E; Mirzayev F; Centis R; Colvin C; Richardson MD
    Int J Tuberc Lung Dis; 2009 Oct; 13(10):1305-8. PubMed ID: 19793438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational 'DOTS plus' for the control of MDR-TB.
    Espinal MA; Dye C; Raviglione M; Kochi A
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):561-3. PubMed ID: 10423218
    [No Abstract]   [Full Text] [Related]  

  • 35. [Theoretical basis for the treatment of tuberculosis].
    Krespine C; Helsens C
    Soins; 1986 Dec; (491-492):38-40. PubMed ID: 3105082
    [No Abstract]   [Full Text] [Related]  

  • 36. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
    Migliori GB; Lange C; Girardi E; Centis R; Besozzi G; Kliiman K; Ortmann J; Matteelli A; Spanevello A; Cirillo DM;
    Clin Infect Dis; 2008 Mar; 46(6):958-9. PubMed ID: 18288911
    [No Abstract]   [Full Text] [Related]  

  • 37. [Risk of acquisition of RFP resistance out of INH resistant RFP susceptible tuberculosis].
    Yoshiyama T; Ito K; Ogata H; Aono A; Wada M
    Kekkaku; 2005 Jan; 80(1):9-14. PubMed ID: 15839057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular mechanisms of the formation of drug resistance of Mycobacterium tuberculosis (review of the literature)].
    Tungusova OS; Mar'iandyshev AO
    Probl Tuberk; 2001; (6):48-9. PubMed ID: 11641963
    [No Abstract]   [Full Text] [Related]  

  • 39. Transmission of isoniazid-resistant tuberculosis.
    Borgdorff MW
    J Infect Dis; 2004 Aug; 190(3):650; author reply 650-1. PubMed ID: 15243944
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes.
    Yoshiyama T; Yanai H; Rhiengtong D; Palittapongarnpim P; Nampaisan O; Supawitkul S; Uthaivorawit W; Mori T
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):31-8. PubMed ID: 14974743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.